Filed under: Investing
ARCA biopharma to Present at the Rodman & Renshaw Annual Global Investment Conference
BROOMFIELD, Colo.--(BUSINESS WIRE)-- ARCA biopharma, Inc. (NAS: ABIO) , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Dr. Michael R. Bristow, will present at the Rodman & Renshaw Annual Global Investment Conference, taking place September 9-10, 2013 at the Millennium Broadway Hotel in New York City. ARCA's presentation will take place Tuesday, September 10, 2013 at 10:25am ET. The Company's presentation will be posted in the Investor Relations section of its website (www.arcabiopharma.com) and will also be available via webcast at: http://wsw.com/webast/rrshq23/ABIO.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the Phase 2B portion of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release and the anticipated presentation contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company's capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the SEC, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.
ARCA biopharma, Inc.
Derek Cole, Investor Relations Advisory Solutions
720-940-2163
derek.cole@arcabiopharma.com
KEYWORDS: United States North America Colorado New York
INDUSTRY KEYWORDS:
The article ARCA biopharma to Present at the Rodman & Renshaw Annual Global Investment Conference originally appeared on Fool.com.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments
